FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103467641> ?p ?o ?g. }

• W2103467641 endingPage "444" @default.
• W2103467641 startingPage "431" @default.
• W2103467641 abstract "Cellular recognition and adhesion to the extracellular matrix (ECM) has a complex molecular basis, involving both integrins and cell surface proteoglycans (PG). The current studies have used specific inhibitors of chondroitin sulfate proteoglycan (CSPG) synthesis along with anti-alpha 4 integrin subunit monoclonal antibodies to demonstrate that human melanoma cell adhesion to an A-chain derived, 33-kD carboxyl-terminal heparin binding fragment of human plasma fibronectin (FN) involves both cell surface CSPG and alpha 4 beta 1 integrin. A direct role for cell surface CSPG in mediating melanoma cell adhesion to this FN fragment was demonstrated by the identification of a cationic synthetic peptide, termed FN-C/H-III, within the fragment. FN-C/H-III is located close to the amino terminal end of the fragment, representing residues #1721-1736 of intact FN. FN-C/H-III binds CSPG directly, can inhibit CSPG binding to the fragment, and promotes melanoma cell adhesion by a CSPG-dependent, alpha 4 beta 1 integrin-independent mechanism. A scrambled version of FN-C/H-III does not inhibit CSPG binding or cell adhesion to the fragment or to FN-C/H-III, indicating that the primary sequence of FN-C/H-III is important for its biological properties. Previous studies have identified three other synthetic peptides from within this 33-kD FN fragment that promote cell adhesion by an arginyl-glycyl-aspartic acid (RGD) independent mechanism. Two of these synthetic peptides (FN-C/H-I and FN-C/H-II) bind heparin and promote cell adhesion, implicating cell surface PG in mediating cellular recognition of these two peptides. Additionally, a third synthetic peptide, CS1, is located in close proximity to FN-C/H-I and FN-C/H-II and it promotes cell adhesion by an alpha 4 beta 1 integrin-dependent mechanism. In contrast to FN-C/H-III, cellular recognition of these three peptides involved contributions from both CSPG and alpha 4 integrin subunits. Of particular importance are observations demonstrating that CS1-mediated melanoma cell adhesion could be inhibited by interfering with CSPG synthesis or expression. Since CS1 does not bind CSPG, the results suggest that CSPG may modify the function and/or activity of alpha 4 beta 1 integrin on the surface of human melanoma cells. Together, these results support a model in which the PG and integrin binding sites within the 33-kD fragment may act in concert to focus these two cell adhesion receptors into close proximity on the cell surface, thereby influencing initial cellular recognition events that contribute to melanoma cell adhesion on this fragment." @default.
• W2103467641 created "2016-06-24" @default.
• W2103467641 creator A5000085125 @default.
• W2103467641 creator A5017451587 @default.
• W2103467641 creator A5061651233 @default.
• W2103467641 creator A5078768906 @default.
• W2103467641 creator A5083138923 @default.
• W2103467641 date "1992-07-15" @default.
• W2103467641 modified "2023-10-18" @default.
• W2103467641 title "Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin." @default.
• W2103467641 cites W1481596686 @default.
• W2103467641 cites W1507059995 @default.
• W2103467641 cites W1520513696 @default.
• W2103467641 cites W1531518952 @default.
• W2103467641 cites W1549492646 @default.
• W2103467641 cites W1558451333 @default.
• W2103467641 cites W1568864185 @default.
• W2103467641 cites W1581375878 @default.
• W2103467641 cites W1605153099 @default.
• W2103467641 cites W1624807108 @default.
• W2103467641 cites W1679707032 @default.
• W2103467641 cites W1914826828 @default.
• W2103467641 cites W1966286149 @default.
• W2103467641 cites W1975304761 @default.
• W2103467641 cites W1975364338 @default.
• W2103467641 cites W1980193009 @default.
• W2103467641 cites W1990387345 @default.
• W2103467641 cites W2000724318 @default.
• W2103467641 cites W2007905457 @default.
• W2103467641 cites W2013381560 @default.
• W2103467641 cites W2026182092 @default.
• W2103467641 cites W2027580030 @default.
• W2103467641 cites W2028253988 @default.
• W2103467641 cites W2037588602 @default.
• W2103467641 cites W2062582674 @default.
• W2103467641 cites W2096133301 @default.
• W2103467641 cites W2103951942 @default.
• W2103467641 cites W2104685950 @default.
• W2103467641 cites W2106200811 @default.
• W2103467641 cites W2108674983 @default.
• W2103467641 cites W2109234770 @default.
• W2103467641 cites W2139666587 @default.
• W2103467641 cites W2149429580 @default.
• W2103467641 cites W2156411608 @default.
• W2103467641 cites W2157698484 @default.
• W2103467641 cites W2165356775 @default.
• W2103467641 cites W2166158504 @default.
• W2103467641 cites W2166227856 @default.
• W2103467641 cites W2166412027 @default.
• W2103467641 cites W2169318446 @default.
• W2103467641 cites W2465817473 @default.
• W2103467641 cites W274186138 @default.
• W2103467641 cites W34966227 @default.
• W2103467641 cites W35496378 @default.
• W2103467641 cites W4232671899 @default.
• W2103467641 cites W4256468456 @default.
• W2103467641 cites W97802624 @default.
• W2103467641 doi "https://doi.org/10.1083/jcb.118.2.431" @default.
• W2103467641 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2290058" @default.
• W2103467641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1629241" @default.
• W2103467641 hasPublicationYear "1992" @default.
• W2103467641 type Work @default.
• W2103467641 sameAs 2103467641 @default.
• W2103467641 citedByCount "158" @default.
• W2103467641 countsByYear W21034676412012 @default.
• W2103467641 countsByYear W21034676412013 @default.
• W2103467641 countsByYear W21034676412014 @default.
• W2103467641 countsByYear W21034676412015 @default.
• W2103467641 countsByYear W21034676412016 @default.
• W2103467641 countsByYear W21034676412018 @default.
• W2103467641 countsByYear W21034676412020 @default.
• W2103467641 countsByYear W21034676412022 @default.
• W2103467641 countsByYear W21034676412023 @default.
• W2103467641 crossrefType "journal-article" @default.
• W2103467641 hasAuthorship W2103467641A5000085125 @default.
• W2103467641 hasAuthorship W2103467641A5017451587 @default.
• W2103467641 hasAuthorship W2103467641A5061651233 @default.
• W2103467641 hasAuthorship W2103467641A5078768906 @default.
• W2103467641 hasAuthorship W2103467641A5083138923 @default.
• W2103467641 hasBestOaLocation W21034676411 @default.
• W2103467641 hasConcept C122871604 @default.
• W2103467641 hasConcept C1491633281 @default.
• W2103467641 hasConcept C153074725 @default.
• W2103467641 hasConcept C153911025 @default.
• W2103467641 hasConcept C16224149 @default.
• W2103467641 hasConcept C164144092 @default.
• W2103467641 hasConcept C189165786 @default.
• W2103467641 hasConcept C195687474 @default.
• W2103467641 hasConcept C2775895372 @default.
• W2103467641 hasConcept C2777141677 @default.
• W2103467641 hasConcept C2779335624 @default.
• W2103467641 hasConcept C2779553658 @default.
• W2103467641 hasConcept C55493867 @default.
• W2103467641 hasConcept C85789140 @default.
• W2103467641 hasConcept C86492073 @default.
• W2103467641 hasConcept C86803240 @default.
• W2103467641 hasConcept C95444343 @default.
• W2103467641 hasConceptScore W2103467641C122871604 @default.

• next